ARSMO Plastic Aesthetic Hospital Introduces Liquid PCL Implant GOURI in Hainan
ARSMO Plastic Aesthetic Hospital Holding Co., Ltd. has announced the inaugural application of GOURI, a...
Fineline Cube
CARsgen Therapeutics’ BCMA-targeted CAR-T Cell Therapy Approved by China’s NMPA
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based...
FDA Withdraws Approval for Multiple Myeloma Drug Pepaxto Over Safety and Efficacy Concerns
The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval...
Chia Tai Tianqing’s Anlotinib-Benmelstobart Combo Therapy Receives CDE Review for Endometrial Cancer
Chia Tai Tianqing, a renowned biopharmaceutical company based in China, has announced that the Center...
CanSino Biologics’ 13-Valent Pneumococcal Vaccine CRM197 Accepted for NMPA Review
CanSino Biologics Inc., (HKG: 6185), a leading Chinese biopharmaceutical company, has announced that the National...
Jenscare Scientific Achieves Milestone with First LuX-Valve Plus Implantation in Brazil
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...
Viatris Secures Late-Stage Programs from Idorsia with Potential for Future Asset Additions
US pharmaceutical company Viatris (NASDAQ: VTRS) has entered into a licensing agreement with Swiss drugmaker...
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
HutchMed’s 2023 Financials Show 102% YOY Revenue Growth and Robust Collaboration with Takeda
HutchMed (HKG: 0013, NASDAQ: HCM), a China-based biopharmaceutical company, has released its financial report for...
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced...
BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant...
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE)...
AstraZeneca’s AZD0486 Receives NMPA Greenlight for Clinical Study in B-Cell Leukemia
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, has received approval from the National Medical...
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to...
BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy
Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application...
Abbisko Therapeutics Reports Positive Phase I Results for ABSK061 in Solid Tumors at ESMO TAT 2024
Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) has revealed promising outcomes from a global, multi-center...
Cutia Therapeutic’s CU-20401 Shows Promising Safety and Efficacy in Phase I Abdominal Fat Reduction Study
Cutia Therapeutic (HKG: 2487), a China-based dermatology specialist, has announced the successful completion of a...
Shandong Buchang Pharmaceuticals Gets NMPA Greenlight for Phase I Study of BC001 in Solid Tumors
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a Chinese pharmaceutical company, has announced that it...
Bayer’s BAY 2927088 Receives FDA Breakthrough Therapy Designation for HER2-Mutated NSCLC
The US Food and Drug Administration (FDA) has granted Germany-based Bayer AG (ETR: BAYN) breakthrough...